Skip to main content

Table 1 BP ND of [ 11 C]AF150(S) before and after treatment with various muscarinic agents

From: [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

Brain region Xanomeline Xanomeline Pirenzepine Trihexyphenidyl Darifenacin Mean
  (5 mg kg −1SC) (30 mg kg −1SC) (30 mg kg −1SC) (3 mg kg −1SC) (3 mg kg −1IV) (n= 20)
  Baseline Pre-treated Baseline Pre-treated Baseline Pre-treated Baseline Pre-treated Baseline Pre-treated Baseline
Left striatum 0.25 ± 0.05 0.30 ± 0.04* 0.22 ± 0.07 0.22 ± 0.05 0.25 ± 0.04 0.21 ± 0.05* 0.24 ± 0.02 0.21 ± 0.01 0.29 ± 0.03 0.28 ± 0.04 0.25 ± 0.05a
Right striatum 0.24 ± 0.04 0.27 ± 0.01 0.23 ± 0.08 0.25 ± 0.06 0.25 ± 0.06 0.23 ± 0.03 0.22 ± 0.01 0.22 ± 0.01 0.26 ± 0.05 0.26 ± 0.03 0.24 ± 0.05b
Hippocampus 0.20 ± 0.03 0.24 ± 0.01* 0.19 ± 0.04 0.19 ± 0.06 0.20 ± 0.03 0.18 ± 0.02 0.19 ± 0.01 0.16 ± 0.01** 0.24 ± 0.02 0.22 ± 0.04 0.20 ± 0.03c
Frontal cortical area 0.12 ± 0.07 0.10 ± 0.04 0.17 ± 0.06 0.14 ± 0.04 0.16 ± 0.05 0.10 ± 0.04** 0.11 ± 0.03 0.05 ± 0.03* 0.22 ± 0.02 0.20 ± 0.06 0.16 ± 0.06d
Posterior cortical area 0.12 ± 0.06 0.10 ± 0.04 0.15 ± 0.06 0.13 ± 0.04 0.13 ± 0.03 0.09 ± 0.03** 0.11 ± 0.05 0.05 ± 0.03* 0.23 ± 0.01 0.18 ± 0.05 0.15 ± 0.06e
  1. Data are presented as mean ± SD (n = 4 per group). IV, intravenous; SC, subcutaneous. Significant difference compared with baseline: * p < 0.05, ** p < 0.01. Significantly different, with p < 0.001: aall regions (except for right striatum), ball regions (except for left striatum), ccompared to all other brain regions, dall regions (except for the posterior cortical area), or eall regions (except for the frontal cortical area).